CENTOGENE raises Euro 25 million
CENTOGENE AG already commands the largest test portfolio for rare genetic diagnostics in the world having analyzed patients from over 110 countries, allowing CENTOGENE to generate unique and global insights into the epidemiological basis of hereditary disorders and the link between genotypic and phenotypic data. “There is a large unmet need for early and easy diagnosis and treatment of rare hereditary diseases.
This creates a tremendous market opportunity for us”, comments Prof. Arndt Rolfs, MD, CEO and Founder of CENTOGENE AG. “We are very pleased to have this international investor consortium on board who not only shares our vision for future growth to put innovation into precision medicine, but also provides the necessary access to an international network to realize our vision on a real global basis.”
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.